Astellas Launches Graceptor In Japan
This article was originally published in PharmAsia News
Astellas announced it launched a once-daily capsule of immunosuppressant Graceptor (tacrolimus) Oct. 28 in Japan. The modified release drug uses the same ingredient as twice-daily Prograf. As patent protection for Astellas' blockbuster drug Prograf is to expire by December 2010, the company launched the modified release version to maximum profits. Graceptor is currently available in 19 countries, and is sold under the name Advagraf in Germany. An approval application in the U.S. is delayed as U.S. FDA requested the company to submit additional data to show efficacy. (Click here for more - Japanese language
You may also be interested in...
TOKYO - Astellas is gearing up to launch its immunosuppressant Prograf in India in 2009 as a first-hand stab at penetrating into the Indian market with the Nov. 14 founding of its subsidiary, Astellas Pharma India Private Ltd. in Mumbai
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Sixty-nine guidance documents have been posted on the tracker since its last update.
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.